Ab0f57c0-figure-01 (Ab0f57c0 Figure 01)
Tadalafil Tablet
Product Images NDC 73190-032
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 73190-032). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Ab0f57c0-figure-02 (Ab0f57c0 Figure 02)
This text provides data on the mean change from baseline in meters for two groups: Placebo (N=82) and Tadalafil Tablets 40 mg (N=79). Statistical significance is indicated by the p-values displayed in the text. The difference in mean change between the two groups is likely being compared.*
Ab0f57c0-figure-03 (Ab0f57c0 Figure 03)
Description: The text provides statistical data related to a study involving subjects who were administered Tadalafil tablets and Placebo. It includes details such as the number of subjects, demographic information like age distribution and gender, and the change in distance walked measured in meters post-medication. Additionally, it includes placebo-adjusted mean change in minute walk distance and confidence intervals for specific metrics like systolic pulmonary pressure. This information appears to be part of a clinical trial evaluation for Tadalafil tablets.*
Ab0f57c0-figure-04 (Ab0f57c0 Figure 04)
This text appears to be a part of a chart or graph showing the percentage without clinical worsening over time for Tadalafil tablets 40 mg, Tadalafil tablets 20 mg, and Placebo. It also includes a scale of 0 to 150 for time to clinical worsening in days.*
20 mg 60 Tablets (Ab0f57c0 Figure 05)
Figure 1 (Image 01)
Figure 2 (Image 02)
The text provides a list of coadministered drugs and their effects on the pharmacokinetics of Tadalafil. It includes CYP3A inhibitors like Ritonavir and Ketoconazole, CYP3A inducers like Rifampin, Bosentan, and H2 antagonists like nizatidine. The data shows the impact of these drugs on AUC (area under the curve) and Cmax (maximum concentration) values of Tadalafil. The values represent fold changes and 90% confidence intervals relative to Tadalafil alone. This information can be useful for healthcare professionals managing drug interactions involving Tadalafil.*
Figure3 (Image 03)
This text provides information on drug-drug interactions involving CYP1A2, CYP2C9 substrates, and P-glycoprotein substrate diflgfl'é(fl 25 mg qd). It includes data on Cmax and AUC for Warfarin (R-warfarin) and Warfarin (S-warfarin), as well as recommendations for fold change and 90%CI. The general recommendation based on the data presented is no dose adjustment needed for the coadministration of the drugs listed. The text also includes a graph showing the change relative to the coadministered drug alone.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
